There are 48 trials studying RC48 in different cancer types; in breast cancer, there are currently six studies exploring de-escalation, combinatorial therapies, effects on liver metastasis, and HER2-low-expressing breast cancers (NCT05134519, NCT04400695, NCT05331326, NCT03052634, NCT05726175, and NCT03500380). The gene discussed is ERBB2; the disease is breast carcinoma.